Vertex drug for cystic fibrosis wins approval

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello! This is our last edition of the Readout until January 3, so I hope you have a lovely holiday! A thought: If you’re strapped for gift ideas, you could always gift three months to STAT+ for $10. Totally worth it. See you next year!

The need-to-know this morning

• Bristol Myers Squibb said that Sotyktu, which is already approved to treat plaque psoriasis, met the primary endpoint in two Phase 3 trials of patients with psoriatic arthritis.

What to expect after Novo’s CagriSema readout

CagriSema, Novo Nordisk’s next-gen obesity drug that combines semaglutide with the amylin analog cagrilintide, fell short of weight loss projections — leading to an 18% drop in Novo’s stock. Specifically, the drug promoted weight loss of about 20%, significantly below the 25% weight loss target the company had projected.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In